Römerstrasse 8
2513 Möllersdorf
Austria
Phone: (+43-2252)55155-0
Fax: (+43-2252)55155-1
http://www.carediagnostica.com
mail@care.co.at
Company Contacts
Department/ Name Address
Mag. Nadja Scheuringer Tel.: ++43/2252/55155-0
mail@care.co.at
Company Figures
Number of employees 50-99
Export content > 75%
Year of foundation 1982
Area of business Diagnostics
Language: German Language: English Company Profile
Company profile
As an international company, product quality of the highest standard is a matter of course for us – it is an integral part of our responsibility for a safe and reliable diagnosis.
High product quality is the base from which we strive for continued improvements: we are the first European diagnostics company to be awarded CE certification for most of our products. We want to stimulate the market with innovative solutions and thereby become the market leader.
We offer a one-stop service to our customers. Part of this service is the duty to do our very best to fulfil your requirements.
Our underlying principle of ‘take CARE’ in the service of human healthcare is based on research, controlled production processes, world class quality management, as well as constant communication both internally and with our customers.
CARE diagnostica’s good name stands for innovation, superior quality and traditional reliability.
Product Information
03.01.08 Devices and systems for glucose determination units
03.01.08.01 Blood glucose
03.01.08.02 Diagnostic agents / kits for glucose determination
03.01.08.06 Glucose fully automatic determination
03.01.08.12 Reagents for glucose determination
03.01.14 Rapid tests – clinical chemistry
03.01.14.01 Point of care – testing systems
03.02.15 Rapid tests – Immunochemistry
03.02.15.01 Pregnancy tests
03.02.15.02 Infectious desease tests
03.04.06 Rapid tests – Microbiology
GUTplus Test (Gastroscopic Urease Test
Provides fast evidence of the urease enzyme from biopsy samples from the intestinal mucous membrane.
HPy IgA / IgG / IgM
The CARE EIA is a sensitive test to quantify the existence of antibodies against Helicobacter pylori, used when gastritis or ventricular and duodenal ulcers are indicated. An accurate calibration curve is compiled with the exact 5-point calibration, enabling a quantitative anaysis of the patient’s sample.
The interpolated value is given in reference units (RU/ml). The conjugate classes Anti-Human IgA, IgG or IgM are HRP marked. The dilution ratio of the serum sample is 1:2000 for IgA, IgG and IgM. The process steps and incubation period is the same for all tests. The 96 microtiter plates provided comprise 8×12 strips and enable flexible and cost-saving usage, even with small sample volumes.
Each test pack contains 5 calibrators, as well as positive and negative controls and several buffer components.
chlamyCARE-C
The bacterium chlamydia trachomatis can be detected directly with this is new antigen test. This means that this test is also suitable for further check-ups following successful treatment.
The chlamydia trachomatis infection is the most common sexually transmitted disease. This mostly asymptomatic disease is the greatest cause of infection-induced infertility.
An infection can lead to various symptoms and later complications: in women it can cause cervicitis, urethitis, peritoneal symptoms or sterility. In men it can lead to urethritis, prostatitis or epididymitis, and in new-born babies can cause newborn pneumonia or inclusion conjunctivitis.
If the chlamydia trachomatis infection is detected in the early stages, it can prevent later complications such as sterility or the development of other illnesses. For patients this new method of diagnosis enables higher quality treatment.
The chlamyCARE-C test system includes all instruments for use: sterile swabs (one for preparation and one for sample collection), test cassette and buffer bottles A & B. It is not necessary to incubate the sample at 80 C.
chlamyCARE-C detects the presence of antigens already with a 1.6×10 to the power of 4 elementary corpuscles/ml and records – according to clinical user trials – 85.7% sensitivity and 98.3% specificity rates (results in comparison with PCR (Polymerase Chain Reaction)).
helicoCARE
This quick test, suitable for screening for antibodies against Helicobacter pylori, was assessed during an extensive comparative study with histology, ELISA and RUT (Rapid Urease Test).
In contrast to other immunological quick tests, helicoCARE equally identifies various classes of antibodies, in particular the anticardiolipin antibodies IgG, IgA and IgM. In this way it is no longer possible to overlook individual stages of the infection.
These results indicate that helicoCARE is an appropriate point-of-care test. The user can obtain information on the presence of symptoms of an infection within a few minutes, without the use of extensive equipment. What’s more, treatment with antibiotics can be initiated earlier and the spread of the infection reduced.
An examination of whole blood, plasma or serum samples can be undertaken with this quick-to-use and simple testing method, without high equipment investment costs. In addition, patient management is improved.
hemoCARE
The 3-hole testing procedure was introduced in Europe with the heavily- documented Guaiac test, hemoCARE. In the meantime, hemoCARE has established itself world wide as a high quality test to detect traces of blood in the stool.
The 3-hole test method has contributed to the correct diagnosis in an increased number of cases due to the higher sample number. An optimal color development in the result field is achieved by using a modified buffer solution with a stable ph value. The use of high quality filter paper for the hemoCARE product has improved the readability factor of the test result. A well-documented study conducted among over 20.000 patients proves that the Guaiac testing method has been optimised.
The increased test field size allows the user to read the result more easily, even when the color is faint. The increased number of corners in the characteristic 6-cornered test field developed by CARE diagnostica allows for scientific observation, as reaction products accumulate particularly in the corners
immoCARE-C
Due to the oxidation process there is a natural limit to how effective the Guaiac method for diagnosing bowel cancer can be. Cross-reactions with non-specific oxidases in food – especially likely if the patient has not complied with dietary instructions – lead to an inaccurate and therefore unreliable result.
With immoCARE-C – a new testing method for the detection of human haemoglobin in the stool sample based on sensitive antibodies – eating restrictions are no longer necessary, either before or during the testing period. This achieves greater compliance along with improved accuracy. Clinical trials have shown that by lowering the required level of evidence (i.e. the amount of haemoglobin present in the stool) the success rate of polyp detection more than doubles. What’s more, this makes it a particularly effective testing method for early detection.
The sampling of the stool using a buffer in a pre-filled sample container is both more hygienic and user-friendly. The tip of the container is broken off and some of the sample mixture placed on the sample field of the test cassette. The result (purple lines) is easy to read in the result field, and is no longer influenced by the colour of the stool itself.
Since 2000 immoCARE-C has been used in the most extensive longitudinal study using an immunological test for the early detection of colon cancer: more than 130,000 people are taking part in a minimum 5-year study in Eastern Austria (Burgenland).
streptoCARE A
Group A streptococcal infections (streptococcus pyogenes) of the respiratory tract belong to the most common infectious diseases and can lead to terrible after-effects. Nowadays the increase in more critical or deadly infections has led to increased attention being focused on this disease in the field of obstetrics.
As approximately 80% of prescriptions for antibiotics are written for infections that are NOT caused by bacteria, a more accurate diagnosis would lead to increased cost-efficiency in healthcare provision. The decision about whether a case of pharyngitis has a bacterial or viral cause is important because the consequent course of treatment is significantly different for each infection. When patients with suspected acute pharyngitis are tested for streptococcus A, 40% test positive and 60% negative, the latter requiring no antibiotic treatment. In addition, a more controlled and safer use of antibiotics would also reduce the risk of an allergic reaction to penicillin.
The cell culture test method produces a result only after 24-48 hours. That is why doctors prefer a quick antigen test. 86% stated that the quick test facilitates the therapeutic decision.
It is very easy to detect streptococcus A with streptoCARE-A’s sample extraction using a single sample buffer. The sample indicates the presence of the antigen already at a level of 1×105 CFU/ml. The sample can be placed on the test cassette direct from the sample container. The level of test result accuracy is continuously backed up by external studies.
If a Group A streptoccal infection is diagnosed early, more serious infections such as rheumatic fever or acute glomerulonephritis can be avoided. This test helps you do this.
streptoCARE B
Approximately 40% of neonatal infections in the first three days are caused by streptoccus B. The progression is often serious and can lead to meningitis and septic shock. In approximately 50% of babies born to mothers with either a vaginal or an rectal infection this leads to a colonialization. Very often premature babies are effected, which means that an early diagnosis in the pregnant woman is extremely important.
The new streptoCARE B quick test detects a streptococcal B infection within a very short space of time compared to the cell culture method. Incubation at 80° C is also no longer necessary. The test result is ready in 15 minutes and the purple lines are easy to see. Clinical studies prove the reliability of this test result; the test detects a streptococcal B infection at a level of 5×105 CFU/ml.
Another area for use is for the early diagnosis of streptococcus B in newborn babies. The quick test performed on a gastric secretion sample has been successful in clinical trials. The results lead us to recommend streptoCARE B test for such cases. StreptoCARE B’s simplicity increases the quality of patient management, and at the same time enables effective use with small as well as large sample volumes.
viola
Qualitative (+/-) detection of pregnancy from urine using test strips, achieved in a few minutes.
Advantages
high sensitivity: 25 mlU hCG/mL
quick result
easy to use
viola-C
As the first one-step pregnancy test viola set the standard and established itself successfully as the market leader in the German-speaking market. Since then the name ‘viola’ has been associated with quality and reliability by numerous users testing for pregnancy.
Due to continuous improvement in sensitivity the detection level for this pregnancy test has been reduced to 25 mlU hCG/ml, whichm when converted, equates to the concentration of hCG at the time when the period is due. To achieve consistent user quality each production batch is compared with the 3rd WHO standard to ensure it reaches this level of evidence.
violaEARLY-C
As the first one-step pregnancy test viola set the standard and established itself successfully as the market leader in the German-speaking market. Since then the name ‘viola’ has been associated with quality and reliability by numerous users testing for pregnancy.
Continuous improvement to the testing method has resulted in a reduction in the detection limit with violaEARLY-C to 12 mU hCG/ml. This means that pregnancy can be detected 7-12 days after conception. This is an innovation in as far a pregnancy can be detected at the lowest possible level at which a pregnancy is indicated. To achieve consistent user quality each production batch is compared with the 3rd WHO standard to ensure it reaches this level of evidence. ViolaEARLY-C is available as a test cassette with pipette.